Sarepta Therapeutics
Market Cap
US$7.6b
Last Updated
2021/01/21 00:06 UTC
Data Sources
Company Financials +
Executive Summary
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Sarepta Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRPT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: SRPT's weekly volatility has increased from 10% to 17% over the past year.
Market Performance
7 Day Return
10.9%
SRPT
4.5%
US Biotechs
0.3%
US Market
1 Year Return
-18.2%
SRPT
40.6%
US Biotechs
21.1%
US Market
Return vs Industry: SRPT underperformed the US Biotechs industry which returned 40.6% over the past year.
Return vs Market: SRPT underperformed the US Market which returned 21.1% over the past year.
Shareholder returns
| SRPT | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.9% | 4.5% | 0.3% |
| 30 Day | -45.3% | 6.8% | 3.3% |
| 90 Day | -29.8% | 27.2% | 14.2% |
| 1 Year | -18.2%-18.2% | 42.9%40.6% | 23.8%21.1% |
| 3 Year | 47.1%47.1% | 28.8%22.1% | 45.0%35.4% |
| 5 Year | 711.1%711.1% | 51.3%39.6% | 127.7%102.3% |
Long-Term Price Volatility Vs. Market
How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Imagine Holding Sarepta Therapeutics (NASDAQ:SRPT) Shares While The Price Zoomed 356% Higher1 month ago | Simply Wall St
Should You Review Recent Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?Valuation
Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRPT ($96.76) is trading below our estimate of fair value ($371.59)
Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRPT is overvalued based on its PB Ratio (8.5x) compared to the US Biotechs industry average (4.3x).
Next Steps
Future Growth
How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
56.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SRPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SRPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SRPT's revenue (29.6% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: SRPT's revenue (29.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Sarepta Therapeutics performed over the past 5 years?
-31.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRPT is currently unprofitable.
Growing Profit Margin: SRPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-67.32%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sarepta Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($2.3B) exceed its short term liabilities ($378.4M).
Long Term Liabilities: SRPT's short term assets ($2.3B) exceed its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: SRPT's debt to equity ratio (78.5%) is considered high.
Reducing Debt: SRPT's debt to equity ratio has increased from 18.7% to 78.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SRPT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SRPT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.
Next Steps
Dividend
What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Doug Ingram (57 yo)
3.58yrs
Tenure
US$1,387,072
Compensation
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as Director of Relay Therapeutics,...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD1.39M) is below average for companies of similar size in the US market ($USD6.22M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.58yrs | US$1.39m | 0.45% $ 34.6m | |
| Executive Vice President of Technical Operations | 1.17yrs | US$4.73m | no data | |
| Consultant | 0.083yr | US$4.20m | 0.032% $ 2.4m | |
| Executive VP of R&D and Chief Medical Officer | 2.58yrs | US$5.17m | 0.0093% $ 713.2k | |
| Executive VP | 0.083yr | no data | 0.018% $ 1.4m | |
| Executive VP & Chief Scientific Officer | 0.083yr | no data | 0.0091% $ 693.3k | |
| VP, Global Chief Compliance Officer | 0.083yr | no data | no data | |
| Senior Vice President of Global Health Policy and Government & Patient Affairs | 1.33yrs | no data | no data | |
| Senior Vice President of Human Resources | 1.33yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | 0.083yr | no data | no data | |
| Controller & VP | 3.83yrs | no data | 0.010% $ 788.0k | |
| 3.58yrs | US$4.78m | no data |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Management: SRPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.58yrs | US$1.39m | 0.45% $ 34.6m | |
| Independent Director | 1yr | no data | no data | |
| Independent Chairwoman | 5.75yrs | US$606.36k | 0.17% $ 13.3m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | no data | US$562.17k | 0.015% $ 1.1m | |
| Independent Director | 5.58yrs | US$574.37k | 3.96% $ 302.6m | |
| Member of Strategic & Scientific Advisory Board | 5.42yrs | no data | no data | |
| Independent Director | 2.08yrs | US$556.72k | 0.0046% $ 352.0k | |
| Member of Strategic & Scientific Advisory Board | 5.42yrs | no data | no data | |
| Independent Non-Employee Director | 5.58yrs | US$561.33k | 0.0089% $ 682.6k | |
| Member of Strategic & Scientific Advisory Board | 3.83yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 3.83yrs | no data | no data |
4.6yrs
Average Tenure
67yo
Average Age
Experienced Board: SRPT's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Top Shareholders
Company Information
Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sarepta Therapeutics, Inc.
- Ticker: SRPT
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.636b
- Shares outstanding: 78.91m
- Website: https://www.sarepta.com
Number of Employees
Location
- Sarepta Therapeutics, Inc.
- 215 First Street
- Suite 415
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRPT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 1997 |
| AB3A | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1997 |
| 0L35 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1997 |
| S1RP34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 20 REPR 1 COM NPV | BR | BRL | Oct 2020 |
Biography
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities appro...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 00:06 |
| End of Day Share Price | 2021/01/20 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.